KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Debt to Equity (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Debt to Equity data on record, last reported at $0.54 in Q4 2025.

  • For Q4 2025, Debt to Equity fell 28.59% year-over-year to $0.54; the TTM value through Dec 2025 reached $0.54, down 28.59%, while the annual FY2025 figure was $0.54, 28.59% down from the prior year.
  • Debt to Equity reached $0.54 in Q4 2025 per PCRX's latest filing, up from $0.52 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.75 in Q4 2024 and bottomed at $0.12 in Q2 2024.
  • Average Debt to Equity over 5 years is $0.34, with a median of $0.35 recorded in 2025.
  • Peak YoY movement for Debt to Equity: plummeted 68.22% in 2023, then soared 428.36% in 2024.
  • A 5-year view of Debt to Equity shows it stood at $0.49 in 2021, then plummeted by 34.18% to $0.32 in 2022, then tumbled by 56.06% to $0.14 in 2023, then soared by 428.36% to $0.75 in 2024, then dropped by 28.59% to $0.54 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.54 in Q4 2025, $0.52 in Q3 2025, and $0.4 in Q2 2025.